国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

丹麥諾維信Novozymes   
丹麥諾維信公司（Novozymes A/S）成立于1941年,是領導世界酶制劑和微生物領域產品的公司，世界市場份額超過45%，產品銷售遍及全球130多個國家。諾維信總部設在哥本哈根，在30個國家建立了分支機構，員工總數5000人。2007年諾維信全球營業收入74.38億丹麥克朗，凈利潤10.42億丹麥克朗。該公司是丹麥在華最大投資企業之一，自1994年起累計在中國投資超過2億美元，在天津經濟技術開發區和北京中關村科技園區分別建立了酶制劑生產基地和中國首家由外商投資設立的生物技術研發中心。位于天津經濟技術開發區的諾維信（中國）生物技術有限公司是諾維信集團全球三大酶制劑戰略生產基地之一，2008年該公司在天津又新增投資3億人民幣。諾維信公司在江蘇太倉投資建設的蘇州宏達制酶公司四期擴建工程2008年底前已完工并投入使用，使之成為目前全球最大的酶發酵生產基地，主要生產用于生物乙醇工業使用的酶制劑。諾維信公司從2006年6月開始與中國中糧集團進行第二代生物乙醇的技術合作，通過諾維信提供的酶技術，將玉米秸稈、木質素纖維素等原料變為可發酵糖，再變為工業乙醇。

以糧食和經濟作物為原料的第一代燃料乙醇生產從長遠看具有規模限制和不可持續性，而利用秸稈、禾草和森林工業廢棄物等非食用纖維素生產乙醇，不存在與人爭糧的問題，以纖維素為原料的第二代“非糧”生物燃料乙醇是決定未來大規模替代石油的關鍵。諾維信公司從2001年就開始研究該項技術，目前在生產第二代生物乙醇的酶發酵技術上目前處于世界領先水平，現有150人從事該領域的專門研究，并與包括世界生物能源領先企業美國ICM等50多家相關機構建立了研發聯系。諾維信公司在酶領域的技術在2008年開始變得相對成熟，丹麥DONG能源公司今年9月投產的第二代生物乙醇提煉廠就使用了諾維信公司的酶技術。諾維信公司希望能在2010年實現第二代生物乙醇的規模化生產。

諾維信公司非常關注中國能源市場，并希望該技術能在中國發展生物燃料乙醇產業，尤其是第二代“非糧”生物乙醇產業中得到應用，為中國發展清潔能源和節能減排提供技術支持。謝杭生大使向Steen Riisgaard先生通報了當前國內經濟形勢和應對全球經濟衰退的政策措施,以及中國在能源發展領域的政策，對諾維信公司的中國發展戰略表示支持，駐丹使館在此過程中愿提供必要的幫助。

Novozymes is a biotech-based world leader in industrial enzymes and microorganisms. The company produces and sells more than 500 enzyme products in 120 countries. Since 1941, Novozymes has introduced almost every new industrial enzyme on the market, making the company the word’s largest manufacturer of enzymes today.
 Novozymes is the biotech-based world leader in enzymes and microorganisms. We strive towards better business, cleaner environment and better lives. Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance in all areas.

Environment-friendly products
Novozymes' more than 600 products are a key player in the production of thousands of products you use in your everyday life - from the textiles in your clothes to the food you eat.

In more than 40 different industries and 130 countries, our biological solutions improve industrial performance and quality while at the same time saving on water, energy, raw materials and waste.

Solutions for the future
In partnership with customers, technology leaders and other stakeholders, Novozymes' 4,000 employees use nature's diversity and our advanced biotech platform to make these unique qualities available to businesses everywhere.
We imagine a future where our biological solutions create the necessary balance between better business, cleaner environment and better lives.
To get there:

We will drive a significant expansion of the market for industrial biotechnology with enzymes and micro organisms as our basis.

We will find new and improved solutions to serve the market for biopharmaceuticals.

We will achieve double digit growth with a leadership position in all markets served.

Customers and partners throughout the world will seek our collaboration because of what we do and how we do it.

People from all over the world will want to work for us because of what we do and how we do it.

Society will be inspired by our work to choose biological solutions as a key part of the future.
Novozymes to acquire Indian enzyme business

Novozymes acquires Biocon’s enzyme business for an agreed purchase price equivalent to DKK 551 million. Novozymes thereby strengthens its position in India.

Biocon is one of India's leading biotechnology companies, specialising in biopharmaceuticals, contract research, clinical research and enzymes. The company is the leading enzyme player in India, and the enzyme business includes a broad range of industrial enzymes, food additives and process aids. Further, Biocon holds a leading position in the global enzymes market for the juice and wine industries.

“The acquisition of Biocon’s enzyme business provides an important step for Novozymes in strengthening our position on the Indian market, which we believe has an attractive growth potential. The activities of Biocon have a good strategic fit to our existing enzyme business”, says CEO of Novozymes, Steen Riisgaard, “We see several interesting market opportunities combined with synergy potential, making this a very interesting acquisition“, he continues.
[email protected]